ETC-7600
- Generic Name
- ETC-7600
ETC-159 in Combination with Pembrolizumab in Advanced MSS/pMMR Ovarian Cancers
Phase 1
Not yet recruiting
- Conditions
- With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 16
- Registration Number
- NCT06513624
- Locations
- 🇸🇬
National Cancer Centre Singapore, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
Phase 1
Active, not recruiting
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- EDDC (Experimental Drug Development Centre), A*STAR Research Entities
- Target Recruit Count
- 89
- Registration Number
- NCT02521844
- Locations
- 🇺🇸
University of Arizona Cancer Center, 3838 N. Campbell Avenue, RM 2111, Site 203, Tucson, Arizona, United States
🇸🇬National University Hospital, 1E Kent Ridge Road, NUHS Tower Block, Level 7, Site 101, Singapore, Singapore
🇸🇬National Cancer Centre Singapore, 11 Hospital Drive, Site 102, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath